Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 3/20 | 0.42 |
| ▸ | PPARA | Q07869 | 3/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.41 |
| ▸ | PPARG | P37231 | 3/20 | 0.41 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17654322 | 0.94 | MRGPRX4 (0.48) | MRGPRX4CYP19A1CYP11B1CYP11B2KIF11 | |
| SCHEMBL17654527 | 0.92 | MRGPRX4 (0.50) | MRGPRX4CYP19A1CYP11B1CYP11B2KIF11 | |
| SCHEMBL17665560 | 0.86 | MRGPRX4 (0.60) | MRGPRX4KIF11RXRARXRBRXRG | |
| SCHEMBL22483303 | 0.82 | MRGPRX4 (0.47) | MRGPRX4PPARDPPARAPTGDR2PPARG | |
| SCHEMBL30354760 | 0.80 | TAAR1 (0.47) | MRGPRX4CYP19A1CYP11B1CYP11B2PPARD | |
| SCHEMBL23578526 | 0.78 | MRGPRX4 (0.50) | MRGPRX4SSTR4 | |
| SCHEMBL17654431 | 0.78 | KIF11 (0.47) | MRGPRX4KIF11 | |
| SCHEMBL17654334 | 0.78 | MRGPRX4 (0.46) | MRGPRX4CYP19A1SSTR4 | |
| SCHEMBL6248816 | 0.77 | MRGPRX4 (0.55) | MRGPRX4KIF11SSTR4 | |
| SCHEMBL30544776 | 0.76 | CYP11B1 (0.51) | MRGPRX4CYP19A1CYP11B1CYP11B2PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12234229-B2 | Sphingosine kinase inhibitor amidoxime prodrugs | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-02-25 | — | — | US | disclosed |
| US-20230050649-A1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2023-02-16 | — | — | US | disclosed |
| US-20230050649-A1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2023-02-16 | — | — | US | disclosed |
| US-11180489-B2 | Sphingosine kinase inhibitor amidoxime prodrugs | U niversity of Virginia Patent Foundation (US) | 2021-11-23 | — | — | US | disclosed |
| US-11180489-B2 | Sphingosine kinase inhibitor amidoxime prodrugs | U niversity of Virginia Patent Foundation (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3436451-B1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | UNIV VIRGINIA PATENT FOUNDATION (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3436451-B1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | UNIV VIRGINIA PATENT FOUNDATION (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3201181-B1 | SPHINGOSINE KINASE INHIBITORS | VIRGINIA TECH INTELLECTUAL PROPERTIES INC (US) | 2020-12-02 | — | — | EP | disclosed |
| EP-3201181-B1 | SPHINGOSINE KINASE INHIBITORS | VIRGINIA TECH INTELLECTUAL PROPERTIES INC (US) | 2020-12-02 | — | — | EP | disclosed |
| US-20200308159-A1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | SPHYNKX THERAPEUTICS, LLC | 2020-10-01 | — | — | US | disclosed |
| US-20200308159-A1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | SPHYNKX THERAPEUTICS, LLC | 2020-10-01 | — | — | US | disclosed |
| EP-3436451-A1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | University Of Virginia Patent Foundation (US) | 2019-02-06 | — | — | EP | disclosed |
| US-10100022-B2 | Sphingosine kinase inhibitors | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2018-10-16 | — | — | US | disclosed |
| US-20170298032-A1 | SPHINGOSINE KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-10-19 | — | — | US | disclosed |
| US-20170298032-A1 | SPHINGOSINE KINASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-10-19 | — | — | US | disclosed |
| WO-2017172989-A1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | THORPE STEVEN BRANDON (US) | 2017-10-05 | — | — | WO | disclosed |
| WO-2017172989-A1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | THORPE STEVEN BRANDON (US) | 2017-10-05 | — | — | WO | disclosed |
| EP-3201181-A1 | SPHINGOSINE KINASE INHIBITORS | Virginia Tech Intellectual Properties, Inc. (US) | 2017-08-09 | — | — | EP | disclosed |
| WO-2016054261-A1 | SPHINGOSINE KINASE INHIBITORS | LYNCH KEVIN (US) | 2016-04-07 | — | — | WO | disclosed |
| WO-2016054261-A1 | SPHINGOSINE KINASE INHIBITORS | LYNCH KEVIN (US) | 2016-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12234229-B2 | Sphingosine kinase inhibitor amidoxime prodrugs | SPHK1, SPHK2, S1PR2 | MRGPRX4 1098/4885CYP19A1 1172/4885CYP11B1 1112/4885 |
| US-20200308159-A1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | SPHK1, SPHK2, S1PR2 | MRGPRX4 1098/4885CYP19A1 1172/4885CYP11B1 1112/4885 |
| US-10100022-B2 | Sphingosine kinase inhibitors | SPHK1, SPHK2, S1PR2 | MRGPRX4 1068/4885CYP19A1 1551/4885CYP11B1 924/4885 |
| US-20230050649-A1 | SPHINGOSINE KINASE INHIBITOR AMIDOXIME PRODRUGS | SPHK1, SPHK2, S1PR2 | MRGPRX4 1098/4885CYP19A1 1172/4885CYP11B1 1112/4885 |
| US-20170298032-A1 | SPHINGOSINE KINASE INHIBITORS | SPHK1, SPHK2, S1PR2 | MRGPRX4 1068/4885CYP19A1 1551/4885CYP11B1 924/4885 |
| US-11180489-B2 | Sphingosine kinase inhibitor amidoxime prodrugs | SPHK1, SPHK2, S1PR2 | MRGPRX4 1098/4885CYP19A1 1172/4885CYP11B1 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.